These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

894 related items for PubMed ID: 25299967

  • 1. Combination therapy in dyslipidemia: where are we now?
    Catapano AL, Farnier M, Foody JM, Toth PP, Tomassini JE, Brudi P, Tershakovec AM.
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [Abstract] [Full Text] [Related]

  • 2. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 3. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR, Knight M.
    Clin Ther; 2015 Oct 01; 37(10):2153-79. PubMed ID: 26412799
    [Abstract] [Full Text] [Related]

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 01; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 5. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K, Iwahashi N, Endo T, Himeno H, Fukui K, Kobayashi S, Shimizu M, Iwasawa Y, Morita Y, Wada A, Shigemasa T, Mochida Y, Shimizu T, Sawada R, Uchino K, Umemura S, Kimura K.
    Atherosclerosis; 2012 Oct 01; 224(2):454-6. PubMed ID: 22892323
    [Abstract] [Full Text] [Related]

  • 6. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA, Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators.
    Am J Cardiol; 2009 Sep 15; 104(6):798-804. PubMed ID: 19733714
    [Abstract] [Full Text] [Related]

  • 7. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Sep 15; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 8. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, Wasserman SM, Sabatine MS.
    J Am Coll Cardiol; 2014 Feb 11; 63(5):430-3. PubMed ID: 24161333
    [Abstract] [Full Text] [Related]

  • 9. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L.
    Orv Hetil; 2014 Jan 12; 155(2):62-8. PubMed ID: 24389322
    [Abstract] [Full Text] [Related]

  • 10. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
    Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ.
    Am J Cardiol; 2015 Jan 15; 115(2):178-82. PubMed ID: 25432415
    [Abstract] [Full Text] [Related]

  • 11. Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
    Chrysohoou C, Singh S.
    Recent Pat Cardiovasc Drug Discov; 2006 Jan 15; 1(1):73-8. PubMed ID: 18221076
    [Abstract] [Full Text] [Related]

  • 12. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM.
    Circ Cardiovasc Qual Outcomes; 2018 May 15; 11(5):e004652. PubMed ID: 29748356
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tunceli K.
    J Clin Lipidol; 2014 May 15; 8(1):107-16. PubMed ID: 24528691
    [Abstract] [Full Text] [Related]

  • 14. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 15; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 15. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB, Jacobson TA.
    Curr Atheroscler Rep; 2017 Jun 15; 19(6):29. PubMed ID: 28500517
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F, Milionis H, Kostapanos MS, Mikhailidis DP, Elisaf M, Liberopoulos E.
    Curr Med Res Opin; 2015 Feb 15; 31(2):221-8. PubMed ID: 25418708
    [Abstract] [Full Text] [Related]

  • 19. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS, Mikhailidis DP.
    Curr Med Res Opin; 2006 Mar 15; 22(3):511-28. PubMed ID: 16574035
    [Abstract] [Full Text] [Related]

  • 20. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI, Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients.
    J Formos Med Assoc; 2017 Apr 15; 116(4):217-248. PubMed ID: 28242176
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.